Peptides Vietnam LogoPeptides Vietnam
Evidence Review2026Updated 13 Sep 2026

Peptides for Thyroid and Autoimmune Conditions: What the Research Shows

Type "peptides for thyroid" into a search box and the results promise a great deal. This page does the opposite: it reports what the published record actually contains when a peptide meets a thyroid or autoimmune diagnosis, and it leads with the thyroid question because that is what most people are asking. The short version is that the peptides with real human thyroid data are diagnostic tools or early-stage candidates, not treatments, while the compounds sold online as thyroid peptides carry no thyroid trial at all. Every figure below is a study or label figure, marked with its evidence level and its PMID, and none of it is a recommendation.

12

Participants in ATX-GD-59, the one peptide trial in Graves hyperthyroidism (PMID 31194638)

0

Human trials of thymosin alpha 1, thymulin or TRH as a treatment for Hashimoto or Graves (PubMed, 2026-09-13)

2

PubMed records for thymosin alpha-1 with Hashimoto or autoimmune thyroiditis, neither a treatment trial (2026-09-13)

This is general education, not medical advice, and not a diagnosis. Hashimoto thyroiditis, Graves' hyperthyroidism, coeliac disease, lupus and multiple sclerosis are diagnosed, treated and monitored by a doctor, and treatment decisions belong in that consultation. Every dose figure here shows only what a study or a label reported, always marked as not a recommendation, and a result recorded in one disease population is a result in that population only. Nothing below is a protocol or an instruction to use any compound.

Evidence Levels, Read First

The compounds people search under "thyroid" and "autoimmune" do not sit at one level of proof. This ladder sorts them from highest to lowest, and every claim later on the page inherits its rung. A result recorded in one disease population is a result in that population only.

  1. a.FDA-approved for a thyroid indication in humans. Thyrotropin alfa (Thyrogen), a recombinant human TSH, approved as an adjunct in thyroid-cancer follow-up and radioiodine remnant ablation.3 Teprotumumab, a monoclonal antibody, is approved-grade evidence for thyroid eye disease.13
  2. b.Formerly approved, now discontinued human thyroid-diagnostic peptide. TRH (protirelin), the basis of the TRH stimulation test.46
  3. c.Human trial of a peptide in autoimmune thyroid disease. ATX-GD-59 in Graves' hyperthyroidism: phase 1, open label, no control group.11
  4. d.Human trials of immune peptides in other named autoimmune diseases. Glatiramer in multiple sclerosis,14 Nexvax2 in coeliac disease,15 rigerimod (Lupuzor) in lupus,16 larazotide in coeliac disease,18 cibinetide in sarcoidosis.20
  5. e.Animal only, in thyroid autoimmunity. Thymosin alpha 1 in experimental autoimmune thyroiditis.21
  6. f.Animal only, in other autoimmune models. Thymulin in a multiple sclerosis model,27 KPV in colitis.29
  7. g.Autoantigen measured, not administered as a treatment. LL-37 in psoriasis.30
  8. h.Sold as a research peptide, investigational, no thyroid trial. Thymosin alpha 1, thymulin and BPC-157.2328

For hypothyroidism, the 2014 American Thyroid Association task force concluded that levothyroxine should remain the standard of care, and found no strong evidence for the superiority of alternatives.1 The 2016 ATA guideline sets out radioactive iodine, antithyroid drugs and surgery for Graves' hyperthyroidism.2 No research peptide appears in either.

Peptides With Thyroid-Specific Human Data

Start with the honest core: which peptides have any human thyroid data at all. There are three, and none is an established treatment for autoimmune thyroid disease.

TRH (protirelin)

TRH (protirelin) is a tripeptide,8 and it has the deepest human thyroid record of anything here, because it is the basis of the TRH stimulation test. In 16 euthyroid subjects it was given intravenously at 200 micrograms, nasally at 2 mg and orally at 40 mg (trial doses, pharmacokinetic study, not a recommendation, PMID 3137012), with a half-life of 6.5 minutes, and stimulated TSH peaked 30 minutes after peak TRH.6 That is a diagnostic mechanism, not a treatment: the protirelin challenge measures free triiodothyronine, free thyroxine and thyrotropin.7 TRH once held FDA approval as a finished product under two applications, THYREL TRH and THYPINONE, both now discontinued, and DailyMed lists protirelin only as bulk drug-substance powder from chemical suppliers.45 Its human treatment trials were run in other conditions entirely, not in Hashimoto or Graves.8910 No fetched record shows TRH used to treat autoimmune thyroid disease.

Thyrotropin alfa (Thyrogen)

Thyrotropin alfa (Thyrogen) is the clearest FDA-approved, thyroid-specific biologic, but it is a recombinant protein hormone, not a small research peptide: a heterodimeric glycoprotein of a 92-residue and a 118-residue subunit, sequence identical to human pituitary TSH, made in Chinese hamster ovary cells.3 It is approved as an adjunctive diagnostic tool for serum thyroglobulin testing and as an adjunct for radioiodine remnant ablation in well-differentiated thyroid cancer follow-up after thyroidectomy. It is not approved for autoimmune thyroid disease.3

ATX-GD-59

ATX-GD-59 is the one peptide with a human trial in autoimmune thyroid disease. In a first-in-human phase 1, open-label study, 12 participants with previously untreated mild to moderate Graves' hyperthyroidism received 10 intradermal doses over 18 weeks. Of the 10 who received all doses, five reached free triiodothyronine within the reference interval by week 18 and two more improved, seven of 10 responders, while three worsened; TSHR autoantibody change correlated with free triiodothyronine change (r = 0.85, p = 0.002). There was no comparison arm.11 The conflict-of-interest statement lists authors serving as officers, directors, employees or shareholders of Apitope, the developer,11 and a 2025 review places the work among early-phase Graves immunotherapies alongside rituximab, iscalimab, K1-70 and teprotumumab.12 The per-dose microgram amount is not stated in the abstract, so this page prints none.

Study Table

One row per study, thyroid rows first, then the immunotherapy trials in other autoimmune diseases, then the animal work. Where a cell carries a dose figure, its attributed block sits below. TRH and thyrotropin alfa are handled above, because their thyroid use is diagnostic rather than a treatment trial.

CompoundPopulation (n)What was measuredResultDesignPMID
ATX-GD-59 (two thyrotropin receptor peptides)12 participants, 11 female, with previously untreated mild to moderate Graves hyperthyroidismFree thyroid hormones and thyrotropin receptor autoantibodiesOf the 10 who received all 10 doses, five reached free triiodothyronine within the reference interval by week 18 and two more improved; three showed worsening thyrotoxicosis. Autoantibody change tracked free triiodothyronine change, r = 0.85, p = 0.002. No comparison armPhase 1, open label, no control, 10 intradermal doses over 18 weeks31194638
Copolymer 1 (glatiramer acetate)251 patients with relapsing-remitting multiple sclerosis (125 drug, 126 placebo)Two-year relapse rate1.19 against 1.68 on placebo, a 29 percent reduction, p = 0.007. More treated patients improved and more on placebo worsened, p = 0.037Randomised, double-blind, placebo-controlled phase III7617181
Nexvax2 (gluten peptides)179 adults with coeliac disease randomised; the primary endpoint was analysed in the non-homozygous group, 76 on drug and 78 on placeboChange in total gastrointestinal symptom score to a masked gluten challengeMean change 2.86 (SD 2.28) against 2.63 (SD 2.07) on placebo, p = 0.43. It did not reduce acute gluten-induced symptoms and was discontinued after a planned interim analysis of 66 non-homozygous patientsRandomised, double-blind, placebo-controlled phase 236898393
Lupuzor / P140 (rigerimod)149 intention-to-treat patients with systemic lupus erythematosus, added to standard of careSLE Responder Index response at week 1253.1 percent every 4 weeks (p = 0.048) and 45.1 percent every 2 weeks (p = 0.18) against 36.2 percent on placeboRandomised, double-blind, placebo-controlled phase IIb23172751
Larazotide acetate (AT-1001)342 adults with coeliac disease still symptomatic after a year or more gluten-freeSymptom scores over 12 weeks of treatmentPrimary endpoint met at 0.5 mg (P = 0.022). The 1 mg and 2 mg doses were no different than placebo for any endpoint. Doses in the block belowRandomised, double-blind, placebo-controlled, 12 weeks25683116
Larazotide acetate (AT-1001), pooled626 patients with coeliac disease across four randomised trials (465 drug, 161 placebo)Change in lactulose-to-mannitol ratio; symptom rating scalesThe permeability endpoint did not differ significantly from placebo, irrespective of gluten status. Symptom scores favoured the drug in the gluten-challenge subgroupSystematic review and meta-analysis of four randomised trials34339872
Cibinetide (ARA 290)64 subjects with sarcoidosis-associated small nerve fibre loss and neuropathic painChange in corneal nerve fibre area at day 28Placebo-corrected 109 (95 percent CI minus 429 to 647) at 1 mg, 697 (159 to 1236, P = 0.012) at 4 mg, 431 (minus 130 to 992) at 8 mg. Doses in the block belowRandomised phase 2b, 28 days, four arms28475703
Thymosin alpha 1Mice, B10.Br (sensitive) and B10.D2 (resistant) strains with experimental autoimmune thyroiditisThyroid infiltration and functional T-cell subsetsTreatment in the first two weeks suppressed thyroiditis in the sensitive strain and increased it in the resistant strain. Effects were dose dependentAnimal study, two congenic mouse strains3873993
ThymulinMice with relapsing-remitting experimental autoimmune encephalomyelitis, a multiple sclerosis modelSerum cytokines and blood-brain barrier conditionLowered interleukin-6, interleukin-17 and interferon-gamma in serum and supported blood-brain barrier condition. No thyroid outcome was measuredAnimal study, mice37633587
KPV (alpha-MSH 11-13)Mice: dextran sodium sulfate colitis and CD45RB-high transfer colitisBody weight, colonic histology, myeloperoxidase activityEarlier recovery and stronger weight regain; inflammatory infiltrates and colonic myeloperoxidase significantly reducedAnimal study, two murine models18092346

What the Immunotherapy Trials Measured

A shared design runs through the immune-peptide trials: deliver a controlled dose of an antigen tied to the reaction, in a form meant to switch that response off. In autoimmune thyroid disease that idea has reached only phase 1: ATX-GD-59 combined two thyrotropin receptor peptides, given intradermally in Graves' hyperthyroidism, and a 2025 review places it among early-phase work alongside rituximab, iscalimab, K1-70 and teprotumumab.1112

The larger trials sit in other diseases, and each result stays in its own population. Glatiramer acetate, sold as Copaxone, completed a phase III in relapsing-remitting multiple sclerosis.14 Nexvax2 applied the idea to coeliac disease with immunodominant gluten peptides against a saline placebo, and did not reduce acute gluten-induced symptoms.15 Rigerimod reached a positive phase IIb in lupus,16 though a 2023 review examines it alongside epratuzumab, baricitinib and ustekinumab when asking why lupus phase III results have diverged from phase II.17 Larazotide met its primary endpoint at one dose only,18 and a meta-analysis of four trials found its permeability endpoint no different from placebo while symptom scores favoured the drug in the gluten-challenge subgroup.19 Cibinetide reached significance on a corneal nerve endpoint at one of three doses in sarcoidosis.20 None of these is a thyroid result.

Doses Reported

Every figure below is a study or label figure in the house format: an attribution, the figure, then a tag naming the evidence level. None is a recommendation, and none is a dose for a reader to take.

Thyroid-specific, approved and diagnostic peptides:

Thyrotropin alfa (Thyrogen): 0.9 mg intramuscular, then a second 0.9 mg intramuscular 24 hours later, intramuscular only (approved-label dose, thyroid-cancer follow-up, not a recommendation, BLA020898).3

TRH (protirelin), human study doses, none of them a treatment for autoimmune thyroid disease: intravenous 200 micrograms, nasal 2 mg and oral 40 mg (trial doses, pharmacokinetic study, not a recommendation, PMID 3137012);6 lumbar intrathecal 500 micrograms in refractory depression (trial dose, not a recommendation, PMID 9075462);8 protirelin tartrate 4 mg per day intramuscularly in upper motoneuron syndrome (trial dose, not a recommendation, PMID 7875957);9 intravenous 0.1 mg/kg for 29 days in spinal muscular atrophy (trial dose, not a recommendation, PMID 10994885);10 and intravenous 200 micrograms as a thyroid-axis challenge (diagnostic dose, not a recommendation, PMID 8792760).7

Immunotherapy trials in other autoimmune diseases:

  • Glatiramer acetate (copolymer 1): 20 mg by daily subcutaneous injection for 2 years (trial dose, multiple sclerosis phase III, not a recommendation, PMID 7617181).14
  • Rigerimod (Lupuzor): 200 micrograms subcutaneously, one group every 4 weeks and one every 2 weeks, added to standard of care (trial dose, lupus phase IIb, not a recommendation, PMID 23172751).16
  • Larazotide acetate: 0.5 mg, 1 mg or 2 mg three times daily for 12 weeks; the primary endpoint was met at 0.5 mg only (trial doses, coeliac RCT, not a recommendation, PMID 25683116).18
  • Cibinetide (ARA 290): 1 mg, 4 mg or 8 mg per day for 28 days, each against placebo; only the 4 mg arm reached P = 0.012 on the corneal endpoint (trial doses, sarcoidosis phase 2b, not a recommendation, PMID 28475703).20
  • Nexvax2: subcutaneous, twice a week, escalating from 1 microgram to 750 micrograms over 5 weeks, then 900 micrograms per dose maintenance (trial schedule, coeliac phase 2, not a recommendation, PMID 36898393).15

Animal studies (not human evidence):

  • Thymosin alpha 1 in experimental autoimmune thyroiditis: 5 or 10 daily subcutaneous injections at 0.0001 to 0.1 microgram per injection (animal study, mice, subcutaneous, PMID 3873993).21
  • Thymulin in a severe experimental autoimmune encephalomyelitis model: 0.15 mg/kg every other day intraperitoneally (animal study, mice, intraperitoneal, PMID 25662754).27
  • Thymosin fraction 5 in rats: a single 5 mg/kg dose lowered plasma TSH in young rats, while synthetic thymosin alpha 1 up to 5 micrograms/kg had no effect on TSH or thyroid hormones (animal study, rats, PMID 3431174).24

Sold as Thyroid or Research Peptides

These are the compounds people actually find when they search for a thyroid peptide or an autoimmune peptide to buy. What follows is a record of what each vendor page says, quoted and attributed, with no test commissioned by anyone and no first-hand claim. None of these pages claims FDA approval or a therapeutic benefit; each states its product is not for human consumption.333435

Thymosin alpha-1. The rationale published for it describes immune stimulation: a 2016 review by two authors at SciClone Pharmaceuticals states that, due to its immune stimulating effects, it would be expected to show utility for treatment of immune suppression, whether related to aging or to diseases such as infection or cancer.22 Its only thyroid-autoimmunity data are animal, in experimental autoimmune thyroiditis, where the direction of effect depended on the mouse strain and was dose dependent.21 A 2026 narrative review of peptides in thyroid health, written by a wellness-clinic medical director in a complementary-medicine journal, concludes that clinical use remains largely investigational in the context of thyroid disease.23 Sold as a research chemical, one vendor lists it at $ 125.00 / 10 mg as a synthetic 28-amino-acid peptide for laboratory research, marked For Laboratory and Research Use Only and not approved by the FDA.33 More on the thymosin alpha-1 page.

Thymulin. Its autoimmune evidence is animal only, in the experimental autoimmune encephalomyelitis model of multiple sclerosis, where across three studies it lowered cytokines and reduced disease severity in mice.252627 No fetched record shows a human thyroid trial of thymulin. One vendor lists Thymulin (Thymalin) 10MG at a $23.99 sale price, down from $29.99, for laboratory research purposes only, not for human consumption.35

TRH (protirelin). The same tripeptide that drives the diagnostic TRH test is also sold as a research chemical: one vendor lists it at 31.66 USD as a research peptide consisting of the tripeptide sequence pGlu-His-Pro-NH2 that modulates pituitary secretion of thyrotropin, marked for research use only, not for human consumption.34 That thyroid-axis language is why it surfaces in searches for a thyroid peptide, but the listing itself makes no treatment claim, and its finished US products are discontinued.4

BPC-157. A 2026 review reports that its pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen and no completed phase II clinical trial, and that available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies.28 It has no thyroid trial. Background sits on our BPC-157 page.

KPV. KPV is the tripeptide tail of alpha-melanocyte-stimulating hormone, and its colitis result was recorded in two murine models, not in patients.29 The inflammation-marker material sits on our peptides and inflammation guide; this page does not restate it.

LL-37. LL-37 was measured as a T-cell autoantigen, not administered as a treatment: a 2014 study reported that two-thirds of patients with moderate to severe plaque psoriasis harbour T cells specific for LL37, and that circulating LL37-specific T cells correlate with disease activity.30

Thyroid-Adjacent Human Evidence That Is Not a Research Peptide

Two things people meet in the same search sit above every research peptide on the evidence ladder, while being outside the peptide class. Teprotumumab is a monoclonal antibody against the insulin-like growth factor I receptor, not a peptide; it produced an 83 percent proptosis response at week 24 against 10 percent on placebo in 41 versus 42 patients with active thyroid eye disease, P below 0.001.13 Selenium is a mineral, not a peptide: a 2023 overview of six systematic reviews covering 75 randomised trials in autoimmune thyroiditis reported thyroid peroxidase antibody reductions at 3 and 6 months in both the levothyroxine-treated and untreated groups, with no reduction at 12 months in the untreated group, on low certainty of evidence.31

Clinicians monitor thyroid peroxidase antibodies, thyrotropin receptor antibodies, TSH and free hormone levels. Local panels are covered in our blood testing guide, and the wider endocrine picture sits in the hormones guide.

Direction of Effect: What One Meta-Analysis Measured

A meta-analysis of 38 randomised trials covering 7,551 patients with advanced solid tumours measured endocrine adverse events across immune checkpoint inhibitor regimens. Compared with ipilimumab, patients on combination PD-1 plus CTLA-4 therapy had higher odds of hypothyroidism (odds ratio 3.81, 95 percent CI 2.10 to 6.91, P below 0.001) and of hyperthyroidism (odds ratio 4.27, 95 percent CI 2.05 to 8.90, P = 0.001); patients on PD-1 inhibitors had higher odds of hypothyroidism (odds ratio 1.89, 95 percent CI 1.17 to 3.05, P = 0.03).32

What that measured, and what it did not. Those are cancer drugs, antibodies, given to cancer patients, and the analysis measured endocrine adverse events. It documents that when immune activation is increased deliberately in humans, thyroid dysfunction shows up in the results. It is not evidence that any research peptide treats thyroid disease, and anyone weighing an immune-active compound against a thyroid antibody result has a question for their doctor.32

In Vietnam: What Is Registered, and What Is Not

On the Vietnamese side the pattern matches the evidence ladder: the conventional thyroid medicines are registered, and the research peptides are not what turns up. This reads from one directory that was reachable this session, thuocbietduoc.com.vn, which lists a registration number (So dang ky) and active ingredient but no price and no prescription flag, so it is an information directory, not a storefront. Levothyroxine, the standard of care,1 appears under several brands: Berlthyrox 100 (registration 400110179525, Berlin-Chemie), Levothyrox (registration VN-0943-06, MSD Vietnam) and Levothyrox 25mcg (registration VN-5534-01), grouped as hormones and endocrine agents. Desiccated thyroid appears as Thyroid 100mg (freeze-dried thyroid powder, registration VNA-3898-00), and the antithyroid drug carbimazole as Carbimazol 5mg. No research peptide sits among them.36

Thymosin alpha 1 is itself registered in Vietnam, but as a licensed pharmaceutical under the name thymalfasin, not as a thyroid drug: Zadaxin 1,6mg (registration VN-10075-10) and Thymosin alpha 1 for injection (registration VN-13015-11), both lyophilised powder for injection. That is the licensed immune or hepatitis product, a different thing from the research-chemical vial sold online.36

Two searches returned nothing in this directory: Thyrogen (recombinant human TSH) and protirelin or TRH were both empty, while thyrotropin and TRH returned only incidental matches inside levothyroxine and octreotide monographs. That is a null for one directory on one day, not a statement about the country. Nha thuoc Long Chau returned an HTTP 403 Cloudflare block on every query and the Drug Administration of Vietnam registry did not respond, so this page makes no claim that recombinant TSH or protirelin is unavailable in Vietnam, only that neither appeared in the one readable directory. Registration validity was not confirmed against the national registry.36 Wider local context sits in our therapeutic peptides in Vietnam guide.

How the Sources Were Searched

Searches ran through the NCBI E-utilities interface on 2026-09-13. Each line records the query as submitted, the count, and where the count is small enough, the records. A count is a fact about a search on a date, not a claim about the world, and a compound can be indexed under a synonym a name-only query misses.

  • "thymosin alpha-1"[tiab] AND (Hashimoto[tiab] OR "autoimmune thyroiditis"[tiab]) returned 2 records on 2026-09-13: PMID 42222211, a 2026 narrative review, and PMID 3873993, a 1985 mouse study. Neither is a human treatment trial.
  • ("thymosin alpha-1"[tiab] OR "thymosin alpha 1"[tiab] OR thymalfasin[tiab]) AND (thyroid*[tiab] OR Hashimoto[tiab] OR Graves[tiab]) returned 10 on 2026-09-13; the 8 not already counted are older thymus-biology or co-occurrence records, none a human thyroid-treatment trial.
  • thymulin[tiab] AND (thyroid*[tiab] OR autoimmun*[tiab] OR thyroiditis[tiab] OR Graves[tiab] OR Hashimoto[tiab]) returned 56 on 2026-09-13.
  • (protirelin[tiab] OR "thyrotropin-releasing hormone"[tiab] OR "thyrotropin releasing hormone"[tiab]) AND thyroid[tiab] AND humans[mh] returned 1069 on 2026-09-13, dominated by the diagnostic TRH stimulation test and thyroid-axis physiology, not treatment trials.
  • protirelin[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt]) returned 17 on 2026-09-13; the titles cover depression, schizophrenia, stroke sequelae, spinal muscular atrophy and pharmacokinetics, none a treatment trial in autoimmune thyroid disease.
  • peptide immunotherapy AND (Hashimoto OR "thyroiditis, autoimmune"[mh]) returned 308 on 2026-09-13.
  • ("antigen-specific immunotherapy"[tiab] OR "peptide immunotherapy"[tiab]) AND autoimmune[tiab] AND meta-analysis[pt] returned 0 on 2026-09-13, so there is no meta-analysis of antigen-specific peptide immunotherapy across autoimmune disease to cite.

Frequently Asked Questions

Is there a peptide proven to treat thyroid disease?+

Not in the fetched record. The peptides with any human thyroid data are diagnostic or early stage, not established treatments. TRH (protirelin), a tripeptide, is the basis of the TRH stimulation test that probes the pituitary-thyroid axis (PMID 3137012), and its two finished US products, THYREL TRH and THYPINONE, are discontinued on the Drugs@FDA record. Thyrotropin alfa (Thyrogen), a recombinant human TSH, is FDA approved only as an adjunct in thyroid-cancer follow-up and radioiodine remnant ablation, not for autoimmune thyroid disease (BLA020898). ATX-GD-59, a pair of thyrotropin receptor peptides, was tested in Graves hyperthyroidism in a single phase 1 open-label study with no control group (PMID 31194638). For hypothyroidism, the 2014 American Thyroid Association task force concluded that levothyroxine should remain the standard of care (PMID 25266247).

Does thymosin alpha 1 help Hashimoto or autoimmune thyroid disease?+

The only thyroid-autoimmunity data for thymosin alpha 1 are from animals. In a 1985 study of experimental autoimmune thyroiditis in two congenic mouse strains, its direction of effect depended on which strain was treated and was dose dependent (PMID 3873993). A 2026 narrative review of peptides in thyroid health states that available data consist primarily of preclinical investigations, mechanistic studies and early exploratory clinical reports rather than large randomised trials focused on thyroid-specific outcomes, and that clinical use remains largely investigational in the context of thyroid disease (PMID 42222211). A PubMed search for thymosin alpha-1 with Hashimoto or autoimmune thyroiditis returned only those two records on 2026-09-13. Whether it suits any individual is a question for the treating clinician.

What does an open-label trial with no control group change about a result?+

It removes the comparison that makes a percentage interpretable. The ATX-GD-59 study was phase 1 and open label: participants knew what they were receiving and there was no placebo arm, so its responder figure cannot be separated from the natural course of untreated mild to moderate hyperthyroidism. Its conflict-of-interest statement lists authors serving as officers, directors, employees or shareholders of Apitope, the company developing it (PMID 31194638).

Why does an autoimmune diagnosis change how a peptide sold for immune support is read?+

Because the rationale published for those compounds describes immune stimulation. A 2016 review of thymosin alpha 1 by two authors at SciClone Pharmaceuticals states that, due to its immune stimulating effects, it would be expected to show utility for treatment of immune suppression, whether related to aging or to diseases such as infection or cancer (PMID 27450734). An autoimmune diagnosis describes a response already aimed at the body: at thyroid peroxidase in Hashimoto thyroiditis, at the thyrotropin receptor in Graves disease. Whether a compound suits that setting is a question for the treating clinician alone.

Is a peptide sold online as a thyroid peptide the same as trial material?+

That is a separate question from efficacy, and it is answered per lot. The compounds sold online carry their own labels: one vendor lists thymosin alpha-1 at $ 125.00 / 10 mg as a synthetic 28-amino-acid peptide for laboratory research, marked not for human use and not approved by the FDA, and another lists TRH (protirelin) at 31.66 USD for research use only. Trial material is manufactured to a pharmaceutical specification and documented before a dose is given; outside a trial, identity and purity rest on a certificate of analysis tied to the lot number on the vial. Our guide on verifying a certificate of analysis sets out what those documents show.

What is worth asking the doctor managing a thyroid antibody result?+

These questions keep the conversation on evidence. Which published trial is this suggestion based on, and was that trial run in my disease or a different one? Was it randomised and placebo-controlled, or open label with no comparison group? Does this compound stimulate or suppress the immune response, and which direction does my condition involve? Could it interfere with my medication, or with the thyroid peroxidase antibodies, thyrotropin receptor antibodies, TSH and free hormone levels used to monitor me?

Sources and References

Every figure on this page traces to one of these records, fetched on 2026-09-13. Numbers match the citation markers in the text.

  1. 1.Jonklaas J et al. 2014 ATA guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751. PMID 25266247
  2. 2.Ross DS et al. 2016 ATA guidelines for hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. PMID 27521067
  3. 3.Thyrotropin alfa (THYROGEN), Genzyme. US FDA label and Drugs@FDA BLA020898; label effective 2023-02-24. DailyMed and Drugs@FDA BLA020898
  4. 4.Protirelin (TRH), Drugs@FDA. THYREL TRH (Ferring, NDA018087) and THYPINONE (Abbott, NDA017638), both Discontinued. Fetched 2026-09-13. Drugs@FDA protirelin
  5. 5.DailyMed SPL web service, protirelin: three bulk drug-substance powder listings, no finished-product label. Fetched 2026-09-13. DailyMed SPL protirelin
  6. 6.Duntas L et al. Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man. Dtsch Med Wochenschr. 1988;113(35):1354-1357. PMID 3137012
  7. 7.Duval F et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatry. 1996;53(9):833-840. PMID 8792760
  8. 8.Marangell LB et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54(3):214-222. PMID 9075462
  9. 9.Civardi C et al. Protirelin tartrate (TRH-T) in upper motoneuron syndrome: a controlled study. Ital J Neurol Sci. 1994;15(8):395-406. PMID 7875957
  10. 10.Tzeng AC et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil. 2000;79(5):435-440. PMID 10994885
  11. 11.Pearce SHS et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves hyperthyroidism: a phase I study. Thyroid. 2019;29(7):1003-1011. PMID 31194638
  12. 12.Lee ACH, Kahaly GJ. Targeted immunotherapies for Graves thyroidal and orbital diseases. Front Immunol. 2025;16:1571427. PMID 40145088
  13. 13.Douglas RS et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. PMID 31971679
  14. 14.Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology. 1995;45(7):1268-1276. PMID 7617181
  15. 15.Tye-Din JA et al. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in coeliac disease (RESET CeD). Lancet Gastroenterol Hepatol. 2023;8(5):446-457. PMID 36898393
  16. 16.Zimmer R et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a phase IIb clinical trial. Ann Rheum Dis. 2013;72(11):1830-1835. PMID 23172751
  17. 17.Lorenzo-Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: why have phase III trials failed to confirm phase II results? Ann Rheum Dis. 2023;82(2):169-174. PMID 36202589
  18. 18.Leffler DA et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319.e6. PMID 25683116
  19. 19.Hoilat GJ et al. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of RCTs. Clin Res Hepatol Gastroenterol. 2022;46(1):101782. PMID 34339872
  20. 20.Culver DA et al. Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated small nerve fiber loss. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. PMID 28475703
  21. 21.Tomazic VJ et al. Thymosin alpha 1-induced modulation of cellular responses in mice with experimental autoimmune thyroiditis. Cell Immunol. 1985;93(2):340-349. PMID 3873993
  22. 22.King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-178. PMID 27450734
  23. 23.Mazza AD. Peptide therapies in thyroid health: emerging applications in endocrine and immune modulation. Integr Med (Encinitas). 2026;25(2):29-37. Single-author narrative review. PMID 42222211
  24. 24.Goya RG et al. Age-dependent thyrotropin-inhibiting activity of thymosin peptides. Mech Ageing Dev. 1987;41(3):219-227. PMID 3431174
  25. 25.Lunin SM et al. Protective effect of exogenous peroxiredoxin 6 and thymulin on BBB in an experimental model of multiple sclerosis. Arch Biochem Biophys. 2023;746:109729. PMID 37633587
  26. 26.Lunin SM et al. Protective effect of PBCA nanoparticles loaded with thymulin against relapsing-remitting EAE in mice. Int J Mol Sci. 2019;20(21):5374. PMID 31671728
  27. 27.Lunin SM et al. Modulation of inflammatory response in mice with severe autoimmune disease by thymulin and an NF-kappaB inhibitor. Int Immunopharmacol. 2015;25(2):260-266. PMID 25662754
  28. 28.Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges and translational barriers. Pharmaceutics. 2026;18(5):625. PMID 42198317
  29. 29.Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346
  30. 30.Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. PMID 25470744
  31. 31.Wang YS et al. The effects of selenium supplementation in the treatment of autoimmune thyroiditis: an overview of systematic reviews. Nutrients. 2023;15(14):3194. PMID 37513612
  32. 32.Barroso-Sousa R et al. Incidence of endocrine dysfunction following different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-182. PMID 28973656
  33. 33.American Peptides (americanpeptides.us), product page Thymosin Alpha-1, fetched 2026-09-13. Research-use-only listing; no FDA-approved label. americanpeptides.us
  34. 34.ChemiNova Research Chemicals (cheminovas.com), product page TRH Thyrotropin (Protirelin), fetched 2026-09-13. Research-use-only listing; no FDA-approved label. cheminovas.com
  35. 35.Eros Peptides (erospeptides.com), product page Thymulin (Thymalin) 10MG, fetched 2026-09-13. Research-use-only listing; no FDA-approved label. erospeptides.com
  36. 36.Thuoc Biet Duoc drug directory (thuocbietduoc.com.vn), queried 2026-09-13. Vietnamese information directory: registration numbers and ingredients only, no price and no prescription flag. thuocbietduoc.com.vn

Related Reading

Peptides and Inflammation

Marker studies and their populations

Thymosin Alpha-1

The research peptide with animal-only thyroid data

Therapeutic Peptides in Vietnam

Categories, access and local status

How to Verify a Peptide COA

Identity and purity, checked per lot

This guide is educational and is not medical advice. Autoimmune and thyroid conditions are diagnosed, treated and monitored by a doctor. If you have a diagnosis or take medication, speak to the clinician managing your care before changing anything.

Sources

  1. 1.Jonklaas J et al. 2014 ATA guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751.
  2. 2.Ross DS et al. 2016 ATA guidelines for hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
  3. 3.Thyrotropin alfa (THYROGEN), Genzyme. US FDA label and Drugs@FDA BLA020898; label effective 2023-02-24.
  4. 4.Protirelin (TRH), Drugs@FDA. THYREL TRH (Ferring, NDA018087) and THYPINONE (Abbott, NDA017638), both Discontinued. Fetched 2026-09-13.
  5. 5.DailyMed SPL web service, protirelin: three bulk drug-substance powder listings, no finished-product label. Fetched 2026-09-13.
  6. 6.Duntas L et al. Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man. Dtsch Med Wochenschr. 1988;113(35):1354-1357.
  7. 7.Duval F et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatry. 1996;53(9):833-840.
  8. 8.Marangell LB et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54(3):214-222.
  9. 9.Civardi C et al. Protirelin tartrate (TRH-T) in upper motoneuron syndrome: a controlled study. Ital J Neurol Sci. 1994;15(8):395-406.
  10. 10.Tzeng AC et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil. 2000;79(5):435-440.
  11. 11.Pearce SHS et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves hyperthyroidism: a phase I study. Thyroid. 2019;29(7):1003-1011.
  12. 12.Lee ACH, Kahaly GJ. Targeted immunotherapies for Graves thyroidal and orbital diseases. Front Immunol. 2025;16:1571427.
  13. 13.Douglas RS et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
  14. 14.Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology. 1995;45(7):1268-1276.
  15. 15.Tye-Din JA et al. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in coeliac disease (RESET CeD). Lancet Gastroenterol Hepatol. 2023;8(5):446-457.
  16. 16.Zimmer R et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a phase IIb clinical trial. Ann Rheum Dis. 2013;72(11):1830-1835.
  17. 17.Lorenzo-Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: why have phase III trials failed to confirm phase II results? Ann Rheum Dis. 2023;82(2):169-174.
  18. 18.Leffler DA et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319.e6.
  19. 19.Hoilat GJ et al. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of RCTs. Clin Res Hepatol Gastroenterol. 2022;46(1):101782.
  20. 20.Culver DA et al. Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated small nerve fiber loss. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60.
  21. 21.Tomazic VJ et al. Thymosin alpha 1-induced modulation of cellular responses in mice with experimental autoimmune thyroiditis. Cell Immunol. 1985;93(2):340-349.
  22. 22.King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-178.
  23. 23.Mazza AD. Peptide therapies in thyroid health: emerging applications in endocrine and immune modulation. Integr Med (Encinitas). 2026;25(2):29-37. Single-author narrative review.
  24. 24.Goya RG et al. Age-dependent thyrotropin-inhibiting activity of thymosin peptides. Mech Ageing Dev. 1987;41(3):219-227.
  25. 25.Lunin SM et al. Protective effect of exogenous peroxiredoxin 6 and thymulin on BBB in an experimental model of multiple sclerosis. Arch Biochem Biophys. 2023;746:109729.
  26. 26.Lunin SM et al. Protective effect of PBCA nanoparticles loaded with thymulin against relapsing-remitting EAE in mice. Int J Mol Sci. 2019;20(21):5374.
  27. 27.Lunin SM et al. Modulation of inflammatory response in mice with severe autoimmune disease by thymulin and an NF-kappaB inhibitor. Int Immunopharmacol. 2015;25(2):260-266.
  28. 28.Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges and translational barriers. Pharmaceutics. 2026;18(5):625.
  29. 29.Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
  30. 30.Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621.
  31. 31.Wang YS et al. The effects of selenium supplementation in the treatment of autoimmune thyroiditis: an overview of systematic reviews. Nutrients. 2023;15(14):3194.
  32. 32.Barroso-Sousa R et al. Incidence of endocrine dysfunction following different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-182.
  33. 33.American Peptides (americanpeptides.us), product page Thymosin Alpha-1, fetched 2026-09-13. Research-use-only listing; no FDA-approved label.
  34. 34.ChemiNova Research Chemicals (cheminovas.com), product page TRH Thyrotropin (Protirelin), fetched 2026-09-13. Research-use-only listing; no FDA-approved label.
  35. 35.Eros Peptides (erospeptides.com), product page Thymulin (Thymalin) 10MG, fetched 2026-09-13. Research-use-only listing; no FDA-approved label.
  36. 36.Thuoc Biet Duoc drug directory (thuocbietduoc.com.vn), queried 2026-09-13. Vietnamese information directory: registration numbers and ingredients only, no price and no prescription flag.